Fate Therapeutics Inc. (FATE)
Fate Therapeutics (FATE) Reports Q2 Loss, Tops Revenue Estimates
Fate Therapeutics (FATE) came out with a quarterly loss of $0.33 per share versus the Zacks Consensus Estimate of a loss of $0.47. This compares to loss of $0.54 per share a year ago.
Russell Investments Group Ltd. Acquires 59,267 Shares of Fate Therapeutics, Inc. (NASDAQ:FATE)
Russell Investments Group Ltd. increased its holdings in shares of Fate Therapeutics, Inc. (NASDAQ:FATE – Free Report) by 34.0% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 233,748 shares of the biopharmaceutical company’s stock after purchasing an additional 59,267 shares during the period. Russell Investments Group Ltd. owned 0.24% of Fate Therapeutics worth $874,000 as of its most recent SEC filing. A number of other hedge funds and other institutional investors have also recently modified their holdings of FATE. Fox Run Management L.L.C. purchased a new stake in Fate Therapeutics during the third quarter worth $25,000. Vanguard Personalized Indexing Management LLC bought a new stake in Fate Therapeutics during the third quarter valued at about $30,000. Epiq Partners LLC purchased a new position in Fate Therapeutics in the fourth quarter valued at about $38,000. Nisa Investment Advisors LLC raised its holdings in Fate Therapeutics by 1,069.4% in the fourth quarter. Nisa Investment Advisors LLC now owns 16,840 shares of the biopharmaceutical company’s stock worth $63,000 after purchasing an additional 15,400 shares in the last quarter. Finally, Laurion Capital Management LP lifted its position in shares of Fate Therapeutics by 128.6% during the third quarter. Laurion Capital Management LP now owns 35,173 shares of the biopharmaceutical company’s stock valued at $75,000 after buying an additional 19,787 shares during the last quarter. 97.54% of the stock is currently owned by institutional investors. Fate Therapeutics Trading Down 5.8 % Shares of NASDAQ FATE opened at $3.90 on Monday. The company has a 50 day simple moving average of $5.67 and a two-hundred day simple moving average of $4.84. The stock has a market cap of $443.94 million, a price-to-earnings ratio of -2.03 and a beta of 1.80. Fate Therapeutics, Inc. has a 12 month low of $1.63 and a 12 month high of $8.83. Fate Therapeutics (NASDAQ:FATE – Get Free Report) last posted its earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.47) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.47). The company had revenue of $1.93 million during the quarter, compared to the consensus estimate of $0.80 million. Fate Therapeutics had a negative net margin of 2,933.79% and a negative return on equity of 46.49%. During the same period in the previous year, the firm posted ($0.19) earnings per share. Analysts forecast that Fate Therapeutics, Inc. will post -1.9 EPS for the current year. Analyst Upgrades and Downgrades FATE has been the subject of several recent analyst reports. Oppenheimer reiterated a “market perform” rating on shares of Fate Therapeutics in a research note on Tuesday, February 27th. Wedbush reiterated a “neutral” rating and set a $7.00 price objective on shares of Fate Therapeutics in a report on Monday, May 6th. StockNews.com downgraded Fate Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, May 10th. Morgan Stanley increased their price target on Fate Therapeutics from $3.00 to $7.00 and gave the company an “equal weight” rating in a research note on Tuesday, February 27th. Finally, Barclays upped their price objective on shares of Fate Therapeutics from $6.00 to $10.00 and gave the company an “overweight” rating in a report on Tuesday, February 27th. Two analysts have rated the stock with a sell rating, ten have assigned a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $6.58. Check Out Our Latest Stock Report on Fate Therapeutics Fate Therapeutics Company Profile (Free Report) Fate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders.
Fate Therapeutics, Inc. Expected to Post Q2 2024 Earnings of ($0.40) Per Share (NASDAQ:FATE)
Fate Therapeutics, Inc. (NASDAQ:FATE – Free Report) – Research analysts at HC Wainwright raised their Q2 2024 EPS estimates for Fate Therapeutics in a report released on Thursday, May 16th. HC Wainwright analyst R. Burns now expects that the biopharmaceutical company will post earnings per share of ($0.40) for the quarter, up from their previous forecast of ($0.47). HC Wainwright has a “Neutral” rating and a $5.00 price target on the stock. The consensus estimate for Fate Therapeutics’ current full-year earnings is ($1.90) per share. HC Wainwright also issued estimates for Fate Therapeutics’ Q3 2024 earnings at ($0.44) EPS, Q4 2024 earnings at ($0.45) EPS, FY2024 earnings at ($1.75) EPS, Q1 2025 earnings at ($0.46) EPS, Q2 2025 earnings at ($0.47) EPS, Q3 2025 earnings at ($0.49) EPS, Q4 2025 earnings at ($0.50) EPS and FY2025 earnings at $1.93 EPS. Fate Therapeutics (NASDAQ:FATE – Get Free Report) last released its quarterly earnings data on Thursday, May 9th. The biopharmaceutical company reported ($0.47) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.47). Fate Therapeutics had a negative return on equity of 46.49% and a negative net margin of 2,933.79%. The business had revenue of $1.93 million during the quarter, compared to analysts’ expectations of $0.80 million. During the same period in the prior year, the firm posted ($0.19) EPS. Several other research analysts have also recently issued reports on the stock. Oppenheimer restated a “market perform” rating on shares of Fate Therapeutics in a report on Tuesday, February 27th. Needham & Company LLC restated a “hold” rating on shares of Fate Therapeutics in a report on Thursday, April 11th. Morgan Stanley upped their target price on shares of Fate Therapeutics from $3.00 to $7.00 and gave the company an “equal weight” rating in a report on Tuesday, February 27th. Bank of America upped their target price on shares of Fate Therapeutics from $2.00 to $6.00 and gave the company an “underperform” rating in a report on Thursday, March 28th. Finally, Piper Sandler lowered their target price on shares of Fate Therapeutics from $7.00 to $4.00 and set a “neutral” rating for the company in a report on Friday, May 10th. Two research analysts have rated the stock with a sell rating, ten have given a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $6.58. Check Out Our Latest Analysis on Fate Therapeutics Fate Therapeutics Stock Down 5.8 % Shares of FATE opened at $3.90 on Monday. Fate Therapeutics has a 52-week low of $1.63 and a 52-week high of $8.83. The stock has a 50 day moving average price of $5.67 and a 200 day moving average price of $4.84. The company has a market capitalization of $443.94 million, a price-to-earnings ratio of -2.03 and a beta of 1.80. Hedge Funds Weigh In On Fate Therapeutics A number of large investors have recently bought and sold shares of FATE. Victory Capital Management Inc. increased its holdings in shares of Fate Therapeutics by 22.8% in the 4th quarter. Victory Capital Management Inc. now owns 12,504 shares of the biopharmaceutical company’s stock valued at $47,000 after purchasing an additional 2,322 shares in the last quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. increased its holdings in shares of Fate Therapeutics by 15.1% in the 3rd quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 60,299 shares of the biopharmaceutical company’s stock valued at $128,000 after purchasing an additional 7,916 shares in the last quarter. Epiq Partners LLC purchased a new position in shares of Fate Therapeutics in the 4th quarter valued at about $38,000. Simplicity Wealth LLC purchased a new position in shares of Fate Therapeutics in the 1st quarter valued at about $81,000. Finally, Fox Run Management L.L.C. purchased a new position in shares of Fate Therapeutics in the 3rd quarter valued at about $25,000. Hedge funds and other institutional investors own 97.54% of the company’s stock. About Fate Therapeutics (Get Free Report) Fate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders.
